

Haematologica
HAEMATOL/2016/152710
Version 3

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

Jorge Cortes, Moshe Talpaz, Hedy P. Smith, David S. Snyder, Jean Khoury, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard Larson, David Mitchell, Scott C. Wise, Thomas J. Rutkoski, Bryan D. Smith, Daniel L. Flynn, Hagop M. Kantarjian, Oliver Rosen, and Richard A. Van Etten

Disclosures: JC reports grants from Deciphera, grants and other from BMS, Pfizer and Novartis. RV reports research grants from Deciphera and was on Deciphera's Advisory Board. MT has been on ARIAD's Advisory Board. DS reports personal fees from ARIAD, Novartis and BMS. JPI reports other from BMS, Novartis and ARIAD. RL reports grants from Deciphera. DM reports personal fees from Deciphera. HS reports clinical research support from Deciphera. RE reports grants from National Cancer Institute, Deciphera and has been on Deciphera's Advisory Board. BS, SW, TR, OR, DF are Deciphera employees. HK has been on ARIAD's, Novartis', Pfizer's and BMS' Advisory Board KB has nothing to disclose.

Contributions: JC,BS,DS, KB,HK and RE designed the study.
JC,MT,DS,JK,KB,JPI,RL,HS,and RE enrolled patients and collected data.
JC,BS,DM,SW,TR,HS,DF,HK,OR,and RE performed data analyses and interpretation.
JC,BS,DF,HK,OR,RE wrote the manuscript. All authors reviewed and approved the manuscript.